📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
128 announcements match the current filters (relevance ≥ 5).
JNK India CFO Pravin Sathe Resigns Effective December 16, 2025
JNK India Limited has announced the resignation of Mr. Pravin Sathe from the position of Chief Financial Officer, effective from the close of business hours on December 16, 2025. Mr. Sathe is stepping down to pursue other professional opportunities outside the organization. Consequently, he will also cease to be a Key Managerial Personnel (KMP) and Senior Management Personnel (SMP) of the company. The company has not yet named a successor for the CFO role in this official communication.
Key Highlights
Mr. Pravin Sathe resigned as CFO, KMP, and SMP effective December 16, 2025.
The resignation is attributed to the pursuit of other professional opportunities.
The cessation is effective from the close of business hours on the date of the announcement.
The filing complies with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure a smooth leadership transition. While the resignation appears routine, the timely replacement of a KMP is essential for maintaining financial oversight.
JNK India CFO Pravin Sathe Resigns Effective December 16, 2025
JNK India Limited has announced the resignation of Mr. Pravin Sathe from the position of Chief Financial Officer (CFO), effective from the close of business hours on December 16, 2025. Mr. Sathe is stepping down to pursue other professional opportunities outside the organization. Consequently, he will also cease to be a Key Managerial Personnel (KMP) and Senior Management Personnel (SMP) of the company. The company has not yet named a successor for the CFO role in this specific filing.
Key Highlights
Mr. Pravin Sathe resigned as Chief Financial Officer effective December 16, 2025.
The resignation is attributed to the pursuit of other professional opportunities.
He ceases to be a Key Managerial Personnel (KMP) under Section 203 of the Companies Act, 2013.
The company must appoint a new CFO to ensure continuity in financial reporting and compliance.
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure a smooth leadership transition. While management changes are common, the quality and experience of the successor will be key to maintaining financial stability.
Bank of India to Raise Rs 2,500 Crore via Basel III Compliant Tier II Bonds
Bank of India has announced its plan to raise Rs 2,500 crore through the issuance of Basel III compliant Tier II bonds. This capital raising exercise is designed to strengthen the bank's Tier II capital base and improve its overall Capital Adequacy Ratio (CAR). By opting for Tier II bonds, the bank can augment its regulatory capital without diluting existing shareholder equity. This move supports the bank's long-term credit growth objectives and ensures compliance with stringent RBI capital norms.
Key Highlights
Proposed issuance of Basel III compliant Tier II bonds worth Rs 2,500 crore.
The fundraise aims to strengthen the bank's regulatory capital base.
The move supports future credit expansion and improves the Capital Adequacy Ratio.
Tier II bonds provide a cost-effective way to raise capital without equity dilution.
👀 What to Watch
Investors should monitor the final coupon rate and credit rating of the bonds as indicators of market confidence in the bank's financial health.
Bank of India reappoints Statutory Central Auditors for FY26
Bank of India has reappointed four audit firms as Statutory Central Auditors (SCAs) for the financial year 2025-26, following approval from the Reserve Bank of India. The firms include M/s S Jaykishan, Kolkata; M/s A Bafna & Co., Jaipur; M/s S C V & Co., LLP, New Delhi; and M/s Sarda & Pareek LLP, Mumbai. This reappointment ensures continuity in the auditing process. M/s S Jaykishan, M/s A Bafna & Co. and M/s S C V & Co. LLP are appointed for the 3rd year while M/s Sarda & Pareek LLP is appointed for the 2nd year.
Key Highlights
M/s S Jaykishan, Kolkata (FRN 309005E) reappointed for 3rd year
M/s A Bafna & Co., Jaipur (FRN 003660C) reappointed for 3rd year
M/s S C V & Co., LLP, New Delhi (FRN 000235N) reappointed for 3rd year
M/s Sarda & Pareek LLP, Mumbai (FRN 109262W) reappointed for 2nd year
👀 What to Watch
Investors should note the continuation of these audit firms as it ensures oversight and compliance. Monitor the audit reports for insights into the bank's financial health.
Mankind Pharma Assigned ESG Rating of 71 by NSE Sustainability
Mankind Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 71 for FY25 by NSE Sustainability Ratings and Analytics Limited. This rating was assigned independently based on publicly available information, as the company did not specifically engage the provider for this service. The disclosure is in compliance with SEBI's Master Circular for ESG Rating Providers. A score of 71 suggests a robust framework in sustainability and governance, which is a key metric for institutional and foreign investors.
Key Highlights
NSE Sustainability assigned an ESG rating of 71 to Mankind Pharma for the 2025 financial year.
The rating was assigned independently using publicly available information without company engagement.
The disclosure follows the SEBI Master Circular dated November 11, 2024, regarding ESG Rating Providers.
👀 What to Watch
Monitor how this rating compares to industry peers to gauge the company's relative sustainability standing. This positive score may enhance the stock's attractiveness to ESG-mandated institutional funds.
Bank of India Raises Rs 2,500 Crore via Basel III Tier II Bonds at 7.28% Coupon
Bank of India has successfully raised Rs 2,500 crore through the issuance of Basel III compliant Tier II bonds to strengthen its capital base. The issue received an overwhelming response with total bids of Rs 4,982 crore, representing an oversubscription of 4.98 times the base issue size. The bank exercised its green shoe option of Rs 1,500 crore in addition to the base size of Rs 1,000 crore. The bonds were allotted at a competitive coupon rate of 7.28%, reflecting strong institutional demand.
Key Highlights
Total capital raised amounts to Rs 2,500 crore including a Rs 1,500 crore green shoe option
Issue oversubscribed by 4.98 times with total bids reaching Rs 4,982 crore
Bonds carry a coupon rate of 7.28% and are Basel III compliant Tier II instruments
A total of 68 bids were received on the NSE platform, of which 29 were accepted
The deemed date of allotment for these unsecured, non-convertible bonds is December 12, 2025
👀 What to Watch
The high oversubscription and competitive pricing indicate strong market confidence in the bank's creditworthiness. Investors should view this as a positive step for the bank's capital adequacy and long-term lending capacity.
Mankind Pharma Assigned ESG Rating of 71 by NSE Sustainability for FY25
Mankind Pharma has been assigned an Environmental, Social, and Governance (ESG) rating of 71 by NSE Sustainability Ratings and Analytics Limited for the financial year 2025. This rating was assigned independently by the SEBI-registered provider based on publicly available information, without direct engagement from the company. The disclosure follows the SEBI Master Circular dated November 11, 2024, regarding ESG rating providers. Such ratings are increasingly critical for institutional investors and ESG-focused funds when evaluating non-financial risk and sustainability.
Key Highlights
NSE Sustainability assigned an ESG rating of 71 to Mankind Pharma for FY25.
The rating was conducted independently based on publicly available data without company engagement.
Disclosure is compliant with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155.
The rating provides a benchmark for the company's environmental, social, and governance performance.
👀 What to Watch
Investors should note this rating as it enhances the company's profile for ESG-mandated institutional funds. No immediate portfolio changes are necessary, but the score should be compared against pharmaceutical industry peers.
Bank of India: RBI imposes ₹4,19,550 monetary penalty
Bank of India has disclosed that the Reserve Bank of India (RBI) imposed a monetary penalty of ₹4,19,550 on the bank. The penalty was a result of violations detected in the Chandrapur currency chest, including mutilated notes and inadequate CCTV coverage. The bank stated that this penalty will not have a material impact on its financial operations or other activities. This regulatory action is a reminder of the importance of compliance in banking operations.
Key Highlights
RBI imposed a monetary penalty of ₹4,19,550
Violation related to mutilated notes detected in Chandrapur currency chest
Violation related to inadequate CCTV coverage detected in Chandrapur currency chest
👀 What to Watch
Investors should monitor Bank of India's compliance measures and any further regulatory actions. While the penalty is not material, consistent compliance is crucial for long-term stability.
